BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 6231047)

  • 1. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
    Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
    Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme activities of leukemic cells and biochemical changes induced by deoxycoformycin in vitro--lack of correlation with clinical response.
    Ho AD; Ganeshaguru K; Knauf W; Dietz G; Trede I; Hoffbrand AV; Hunstein W
    Leuk Res; 1989; 13(4):269-78. PubMed ID: 2785618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
    Bagnara AS; Hershfield MS
    Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biochemical and clinical consequences of 2'-deoxycoformycin in T cell chronic lymphocytic leukaemia.
    Hallam LJ; Van der Weyden MB; Ackland SP; Bagnara AS; Whiteside MG
    Scand J Haematol; 1984 Jan; 32(1):55-64. PubMed ID: 6607510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential sensitivity of leukemic cells to growth inhibition by deoxyadenosine and deoxycoformycin.
    Tanaka M; Kimura K
    Tohoku J Exp Med; 1985 Dec; 147(4):331-41. PubMed ID: 3879563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
    Ruers TJ; Buurman WA; van der Linden CJ
    J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inability of poly-ADP-ribosylation inhibitors to protect peripheral blood lymphocytes from the toxic effects of ADA inhibition.
    Ganeshaguru K; Piga A; Latini L; Hoffbrand AV
    Adv Exp Med Biol; 1989; 253B():251-8. PubMed ID: 2532859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes.
    Matsumoto SS; Yu J; Yu AL
    J Immunol; 1983 Dec; 131(6):2762-6. PubMed ID: 6196398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency.
    Goday A; Simmonds HA; Morris GS; Fairbanks LD
    Biochem Pharmacol; 1985 Oct; 34(19):3561-9. PubMed ID: 3876835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
    Kefford RF; Fox RM
    Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow.
    Russell NH; Hoffbrand AV; Bellingham AJ
    Leuk Res; 1986; 10(3):325-9. PubMed ID: 3081767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-adenosylhomocysteine hydrolase inactivation and purine toxicity in cultured human T- and B-lymphoblasts.
    Young GJ; Hallam LJ; Jack I; Van Der Weyden MB
    J Lab Clin Med; 1984 Jul; 104(1):86-95. PubMed ID: 6330251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
    Webster AD; Ip H; Pereira S
    Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relative sensitivity of peripheral blood T-lymphocyte colony forming cells and bone marrow CFU-GM to deoxyadenosine and 2'deoxycoformycin.
    Russell NH; Carron J; Hoffbrand AV; Bellingham AJ
    Leuk Res; 1985; 9(2):315-9. PubMed ID: 3872974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
    Seto S; Carrera CJ; Kubota M; Wasson DB; Carson DA
    J Clin Invest; 1985 Feb; 75(2):377-83. PubMed ID: 2579098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
    Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-Adenosylhomocysteine accumulation and selective cytotoxicity in cultured T- and B-lymphocytes.
    Palella TD; Schatz RA; Wilens TE; Fox IH
    J Lab Clin Med; 1982 Aug; 100(2):269-78. PubMed ID: 6980250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the effect of deoxyadenosine on deoxycoformycin-treated myeloid and lymphoid stem cells.
    Aye MT; Dunne JV; Yang WC
    Blood; 1982 Oct; 60(4):872-6. PubMed ID: 6981441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP depletion as a consequence of adenosine deaminase inhibition in man.
    Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency.
    Albert D; Bluestein HG; Thompson L; Seegmiller JE
    Cell Immunol; 1984 Jul; 86(2):510-7. PubMed ID: 6610485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.